How do I switch from one GLP-1 to another, and what should I expect?

The short answer

Switching from one GLP-1 to another is extremely common — people move for tolerability, results, cost, or supply — and it's also where a specific, avoidable mistake keeps recurring: treating the switch as a dose-for-dose swap.

Evidence tier: Tier 2 — based on the drugs' established potency differences and standard conversion and re-titration practice. This is general guidance; the actual conversion is a prescriber decision specific to your situation.

The essentials:

• It's not a milligram-for-milligram swap — the drugs differ in potency
• Start the new drug low and re-titrate — like a careful restart
• Expect some early side effects to return — tolerance doesn't fully transfer
• Let your prescriber set the conversion and timing — including the gap between drugs

This is a deep dive within our GLP-1 daily-life guide; the escalation logic connects to our titration schedule guide.

Why a switch isn't a dose-for-dose swap

Evidence tier: 2 — established potency differences between agents.

The central mistake is assuming that if you were on, say, a given milligram dose of one drug, you should start the new drug at the "equivalent" milligram dose. The drugs don't work that way. Semaglutide, tirzepatide, and the newer agents differ in potency and in how their dose numbers map to effect, so the same number on two different drugs can mean very different things. Matching milligrams can land you at a dose that's too high (bringing on strong side effects) or too low (losing effect), neither of which is what you want.

There's no universal conversion table you can apply yourself, because the right starting point depends on the specific drugs, your current dose and tolerance, why you're switching, and your history. That's precisely why the conversion is a clinical decision rather than a forum-rule-of-thumb. The safe default mental model is that you're starting a new drug, not continuing at an equivalent dose — and new drugs get introduced at an appropriate starting dose and titrated up.

Why people switch

Evidence tier: 2 — common, legitimate clinical reasons.

Switching is usually driven by one of a handful of reasons, all legitimate:

• Intolerable side effects on the current drug, hoping another is better tolerated.
• A stalled or insufficient response — wanting a potentially stronger agent.
• Cost or insurance changes that make one drug accessible and another not.
• Supply shortages, which have repeatedly pushed people between agents.
• A new option becoming available that fits better.

What matters isn't the reason so much as the approach: each of these is a good basis for a planned, prescriber-guided switch, and none is a reason to improvise an overnight swap at a guessed dose. The reason you're switching also informs the right target — switching for side effects suggests a gentler re-titration; switching for more effect suggests a deliberate climb — which is another argument for involving your clinician rather than self-converting.

What to expect when you switch

Evidence tier: 2 — consistent with the adaptation pattern.

The most important expectation to set: some early side effects often come back. Tolerance to the GI effects you'd built up on the first drug doesn't fully carry over to the second, so the new agent may reintroduce a milder version of the early adaptation — some nausea, GI upset, or appetite changes as you titrate up. This is normal and usually temporary, exactly as it was when you first started, and it's another reason to treat the switch as a careful restart rather than a seamless continuation.

Pacing the new drug's escalation sensibly is what keeps this manageable. Starting low and stepping up patiently — the same logic as any GLP-1 start, covered in our titration schedule guide — spreads the adaptation out and prevents the switch from feeling like starting over at full intensity. People who expect the re-adaptation handle it fine; people who expect to pick up exactly where they left off are caught off guard.

How long between stopping one and starting the next?

Evidence tier: 2 — pharmacokinetic and clinical-judgment factors.

The timing of the transition matters and is a prescriber decision. These are long-acting, typically once-weekly drugs, so they linger in the system after the last dose. That means the interval between stopping one and starting the next has to account for the drugs' half-lives — too short risks overlapping effects, too long creates an unnecessary gap where appetite and weight can rebound.

Because the right interval depends on the specific agents and doses, it's not something to improvise from a forum post. It's part of the conversion your clinician should set, alongside the new starting dose. Getting the timing right is a small detail with real consequences for both tolerability and continuity, and it's exactly the kind of thing professional guidance handles better than guesswork.

A note on gray-market switching

Evidence tier: 2 — sourcing-risk reality.

A specific caution for anyone switching between compounded or gray-market GLP-1s rather than prescribed products: the dose-mapping problem is compounded by uncertain concentration. With approved products, at least the dose you're converting from and to is known. With gray-market vials, the actual concentration may be uncertain, so you're converting between two imprecisely-known doses — which makes a careful, conservative re-titration even more important, and the reconstitution and dosing math another place errors creep in. Verify sourcing via Finnrick, and recognize that switching unverified products multiplies the uncertainty. The cleanest version of any switch is between regulated, prescribed products under medical guidance.

A checklist for a smooth switch

Evidence tier: 2 — synthesis of conversion and re-titration practice.

Putting it together, a well-handled switch follows a predictable sequence — and working through it with your prescriber prevents the common problems:

• Clarify why you're switching. Side effects, insufficient results, cost, or supply each point toward a slightly different target drug and starting approach, so the reason shapes the plan.
• Don't match milligrams. Accept up front that the new drug starts at its own appropriate introductory dose, not the "equivalent" of your old one.
• Set the timing with your prescriber. These long-acting weekly drugs linger, so the interval between stopping one and starting the next needs to account for their half-lives — neither overlapping nor leaving an unnecessary gap.
• Plan to re-titrate. Expect to climb the new drug's dose ladder patiently, the same as a fresh start.
• Expect some early side effects. Tolerance doesn't fully transfer, so brace for a milder version of the initial adaptation and manage it with the usual measures.
• Verify sourcing if gray-market. Uncertain concentrations make a conservative re-titration even more important, and each product needs its own verification.
• Track the transition. Logging dose, timing, and effects through the switch keeps it controlled and gives you (and your clinician) a clear record if anything needs adjusting.

The throughline is that a switch is a managed clinical transition, not a casual swap you can improvise from a forum conversion chart. People who treat it that way — planning the conversion, timing, and re-titration with their prescriber — generally move between drugs smoothly. People who treat it as a same-dose substitution are the ones who end up either under-dosed and losing ground or over-dosed and miserable with side effects. A little planning converts a potentially bumpy change into a routine one.

Limitations

This is an educational guide, not medical advice.

• GLP-1s are prescription medicines — switches, conversions, and timing belong with your prescriber.
• There is no DIY conversion table — the right dose depends on your specifics.
• Some early side effects typically return — treat a switch as a careful restart.
• Gray-market switching adds dose-uncertainty on top of the conversion challenge.
• Compounded/gray-market GLP-1s add sourcing risk — verify via Finnrick.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

Switching between GLP-1s is common and reasonable, but it is not a dose-for-dose swap — the drugs differ in potency and their doses don't map directly, so matching milligrams is the mistake to avoid. Treat a switch as starting a new drug: begin at an appropriate introductory dose and re-titrate, expect some early side effects to return as tolerance doesn't fully transfer, and let your prescriber set both the conversion and the timing between agents. For gray-market products, the uncertain concentrations make a careful, conservative approach even more important. Done as a planned restart rather than an improvised swap, a switch is straightforward; done as a guessed substitution, it invites avoidable side effects.

Related on this site

• Living with a GLP-1: the daily-life guide
• GLP-1 titration schedule
• GLP-1 side effects and how to manage them
• GLP-1 weight-loss plateau
• Reconstitution and dosing guide
• GLP-1 complete guide (2026)
• Next-gen multi-agonists overview
• Our evidence-tier framework
• Finnrick vendor testing

References

• Jastreboff AM, Aronne LJ, Ahmad NN, et al. 2022. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 387(3):205-216. PMID 35658024 — tirzepatide potency and dosing.
• Wilding JPH, Batterham RL, Calanna S, et al. 2021. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 384(11):989-1002. PMID 33567185 — semaglutide dosing and escalation.
• Wharton S, Davies M, Dicker D, et al. 2022. Managing the gastrointestinal side effects of GLP-1 receptor agonists. Postgrad Med. 134(1):14-19. PMID 34775881 — re-titration and tolerability management.
• U.S. Food and Drug Administration. Wegovy / Zepbound prescribing information. FDA.gov — approved dosing and escalation schedules per drug.